Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

被引:108
作者
Zinner, RG
Fossella, FV
Gladish, GW
Glisson, BS
Blumenschein, GR
Papadimitrakopoulou, VA
Pisters, KMW
Kim, ES
Yun, WH
Peeples, BO
Ye, ZS
Curiel, RE
Obasaju, CK
Hong, WK
Herbst, RS
机构
[1] Univ Texas, MD Anderson Canc Ctr, Unit 432, Houston, TX 77030 USA
[2] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
关键词
chemotherapy; platinum; folic acid; vitamin B-12; dexamethasone;
D O I
10.1002/cncr.21480
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The primary objectives of this study were to determine the efficacy and tolerability of a pemetrexed-carboplatin combination as first-line therapy in patients with advanced nonsmall cell lung cancer. METHODS. Eligibility criteria included Zubrod performance status of 0 or 1, Stage IIIB (malignant effusion) or IV disease, and no prior chemotherapy. Treatment was pemetrexed 500 mg/m(2) given intravenously and carboplatin area under the serum concentration-time curve = 6 given intravenously on Day 1 every 3 weeks for six cycles; patients could receive additional cycles at the discretion of the treating physician and patient. All patients received folic acid, vitamin 13,2, and dexamethasone prophylaxis. RESULTS. Fifty patients (31 men and 19 women) were treated. The median age was 62 years. Ninety-six percent of patients had Stage IV disease, and 88% had a performance status of 1. The median number of cycles was 6; 15 patients received 8 or. more cycles. There was Grade 3/4 neutropenia in 11 (22%) and 2 (4%) patients, respectively; Grade 3/4 thronibocytopenia in 1 (2%) and 0 patients, respectively. Three patients (6%) experienced Grade 3 nonhematologic side effects (diarrhea, neutropenic pneumonia, and fatigue). No patients had sensory neuropathy or alopecia > Grade 1. The partial response rate was 24%, median time to progression 5.4 months, 1-year survival 56.0%, and median survival 13.5 months. CONCLUSIONS. This is all active, very well-tolerated regimen. Trials focused on how to integrate this doublet with novel agents are warranted.
引用
收藏
页码:2449 / 2456
页数:8
相关论文
共 37 条
[1]   Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer [J].
Belani, CP ;
Einzig, A ;
Bonomi, P ;
Dobbs, T ;
Capozzoli, MJ ;
Earhart, R ;
Cohen, LJ ;
Luketich, JD .
ANNALS OF ONCOLOGY, 2000, 11 (06) :673-678
[2]  
BUNN PA, 2001, P AN M AM SOC CLIN, V20, P76
[3]   Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer [J].
Clarke, SJ ;
Abratt, R ;
Goedhals, L ;
Boyer, MJ ;
Millward, MJ ;
Ackland, SP .
ANNALS OF ONCOLOGY, 2002, 13 (05) :737-741
[4]  
COON WW, 1976, SURG GYNECOL OBSTET, V143, P385
[5]   Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study [J].
Crino, L ;
Scagliotti, G ;
Marangolo, M ;
Figoli, F ;
Clerici, M ;
DeMarinis, F ;
Salvati, F ;
Cruciani, G ;
Dogliotti, L ;
Pucci, F ;
Paccagnella, A ;
Adamo, V ;
Altavilla, G ;
Incoronato, P ;
Trippetti, M ;
Mosconi, AM ;
Santucci, A ;
Sorbolini, S ;
Oliva, C ;
Tonato, M .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :297-303
[6]   Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group [J].
Fossella, F ;
Pereira, JR ;
von Pawel, J ;
Pluzanska, A ;
Gorbounova, V ;
Kaukel, E ;
Mattson, KV ;
Ramlau, R ;
Szczesna, A ;
Fidias, P ;
Millward, M ;
Belani, CP .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3016-3024
[7]   Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].
Hanna, N ;
Shepherd, FA ;
Fossella, FV ;
Pereira, JR ;
De Marinis, F ;
von Pawel, J ;
Gatzemeier, U ;
Tsao, TCY ;
Pless, M ;
Muller, T ;
Lim, HL ;
Desch, C ;
Szondy, K ;
Gervais, R ;
Shaharyar ;
Manegold, C ;
Paul, S ;
Paoletti, P ;
Einhorn, L ;
Bunn, PA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597
[8]   Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma [J].
Hughes, A ;
Calvert, P ;
Azzabi, A ;
Plummer, R ;
Johnson, R ;
Rusthoven, J ;
Griffin, M ;
Fishwick, K ;
Boddy, AV ;
Verrill, M ;
Calvert, H .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3533-3544
[9]   Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study [J].
Jelic, S ;
Mitrovic, L ;
Radosavljevic, D ;
Elezar, E ;
Babovic, N ;
Kovcin, V ;
Tomasevic, Z ;
Kovacevic, S ;
Gavrilovic, D ;
Radulovic, S .
LUNG CANCER, 2001, 34 (01) :1-13
[10]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481